IRTC — iRhythm Holdings, Inc.
Is IRTC overbought or oversold? Here is the current MarketMoodz read.
iRhythm Holdings, Inc. (IRTC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $110.37. The rating moved from Overbought to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$110.37
- Last changeMoved from Overbought to Oversold on October 1, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
iRhythm Holdings is positioned as a category leader in ambulatory cardiac monitoring with a recurring-service revenue model and secular tailwinds from remote diagnostics and outpatient care growth. The company benefits from established clinical adoption of its Zio offering and potential upside from product upgrades, international expansion, and strategic optionality. That said, near-term sentiment is muted by a risk-off market for digital-health/device equities and potential reimbursement changes under Medicare/MA plans that could affect pricing and utilization. Execution on margin expansion, sustained reimbursement stability, and competitive differentiation will determine upside; downside is primarily tied to payer actions, intensified competition, or macro-driven funding/valuation compression.
Key factors
- Leading market position in ambulatory cardiac monitoring with established Zio platform and recurring analytic revenue
- Strong secular demand for remote diagnostics and cardiac monitoring as care shifts to outpatient and virtual settings
- Revenue mix driven by recurring service and analytics which supports predictable top-line and potential margin expansion
- Product pipeline and incremental instrumentation / software upgrades can drive ARPU and utilization gains
- Potential M&A interest for a category leader in digital cardiac diagnostics, increasing optionality for upside
Risks
- Reimbursement pressure and Medicare/Medicare Advantage changes could reduce payments or shift utilization patterns
- Macro risk-off environment for digital-health and device valuations may compress multiples and limit capital access
- Competition from integrated device/EHR vendors or new wearable entrants could pressure share and pricing
- Operational risks including supply chain disruption for device manufacturing and scale-related cost swings
- Concentration risk from a limited number of large institutional customers or payers and possible collection/revenue timing issues
- Clinical/regulatory setbacks or slower-than-expected adoption of new products and services
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for IRTC — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.